Publication date: Mar 22, 2025
Oral malignant melanoma specifically denotes a rare subtype of melanoma originating in oral mucosa, characterized by a generally poor prognosis. Inhibitors targeting programmed cell death protein-1 or its ligand-1 (PD-1/PD-L1) have become widely accepted as primary treatments for malignant melanoma. The current report describes a unique case of advanced gingival malignant melanoma treated with pembrolizumab monotherapy in a 67-year-old Asian female. The report comprehensively evaluates the therapeutic potential of pembrolizumab, as well as its immune-related adverse events (irAEs).
| Concepts | Keywords |
|---|---|
| Female | Case report |
| Gingival | Oral malignant melanoma |
| Malignant | Pembrolizumab |
| Old | |
| Pembrolizumab |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Pembrolizumab |
| disease | MESH | malignant melanoma |
| pathway | KEGG | Melanoma |
Original Article
(Visited 2 times, 1 visits today)